Cargando…

Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia

Autophagy is a conserved evolutionary process that allows cells to maintain macromolecular synthesis and energy homeostasis during starvation and stressful conditions. We prospectively evaluated the relationship between autophagy and prostatic inflammation in a series of transurethral prostatic rese...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Nunzio, Cosimo, Giglio, Simona, Stoppacciaro, Antonella, Gacci, Mauro, Cirombella, Roberto, Luciani, Emidio, Tubaro, Andrea, Vecchione, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584215/ https://www.ncbi.nlm.nih.gov/pubmed/28881614 http://dx.doi.org/10.18632/oncotarget.15144

Ejemplares similares

A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients
por: Giglio, Simona, et al.
Publicado: (2021)

Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2020)

Correction to: Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2020)

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis
por: Mari, Andrea, et al.
Publicado: (2021)

Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
por: Cindolo, Luca, et al.
Publicado: (2015)

New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives
por: Albisinni, Simone, et al.
Publicado: (2016)

Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia
por: Yu, Haining, et al.
Publicado: (2015)

Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study
por: Gacci, Mauro, et al.
Publicado: (2017)

Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients’ care – a systematic review
por: De Nunzio, Cosimo, et al.
Publicado: (2018)

Pure small cell carcinoma of the prostate: A rare tumor
por: Albisinni, Simone, et al.
Publicado: (2012)

Laparoscopic simple prostatectomy vs bipolar plasma enucleation of the prostate in large benign prostatic hyperplasia: a two-center 3-year comparison
por: Lombardo, Riccardo, et al.
Publicado: (2020)

Measurement of autophagy flux in benign prostatic hyperplasia in vitro
por: Oh, Sung-hee, et al.
Publicado: (2020)

Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Creta, Massimiliano, et al.
Publicado: (2023)

Benign Prostatic Hyperplasia
Publicado: (2015)

Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia
por: Hsiao, Chun-Jen, et al.
Publicado: (2016)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

Obesity and Prostate Cancer: The Tip of a High Mountain Still to Be Conquered
por: Nunzio, Cosimo De, et al.
Publicado: (2020)

Acute urinary tract infection in patients with underlying benign prostatic hyperplasia and prostate cancer
por: Tolani, Musliu Adetola, et al.
Publicado: (2020)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial
por: Rastrelli, G., et al.
Publicado: (2022)

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats
por: Liu, Rong-Fu, et al.
Publicado: (2018)

Correlation between Cholinergic Innervation, Autophagy, and Etiopathology of Benign Prostatic Hyperplasia
por: Cai, Jian-Liang, et al.
Publicado: (2017)

Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancer
por: Zhang, Li, et al.
Publicado: (2016)

Inflammation and Prostate Cancer: Pathological Analysis from Pros-IT CNR 2
por: Sessa, Francesco, et al.
Publicado: (2023)

Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia
por: Pérez-Rambla, Clara, et al.
Publicado: (2017)

The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

Transperineal Laser Ablation of the Prostate (TPLA) for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction
por: Sessa, Francesco, et al.
Publicado: (2023)

Prostatitis and benign prostatic hyperplasia: emerging infectious diseases?
por: Hennenfent, B
Publicado: (1997)

Zinc status in benign prostatic hyperplasia and prostate carcinoma
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia
por: Tenuta, Marta, et al.
Publicado: (2020)

miRNAs as Candidate Biomarker for the Accurate Detection of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neoplasia
por: Giglio, Simona, et al.
Publicado: (2019)

Low Prostate Concentration of Lycopene Is Associated with Development of Prostate Cancer in Patients with High-Grade Prostatic Intraepithelial Neoplasia
por: Mariani, Simone, et al.
Publicado: (2014)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Solving the benign prostatic hyperplasia puzzle
por: Foo, Keong Tatt
Publicado: (2016)

Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_31i2qjhnpoigk6fjfnerjnkjep